AngioDynamics Stock (NASDAQ:ANGO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$7.51

52W Range

$5.26 - $8.25

50D Avg

$7.19

200D Avg

$6.48

Market Cap

$307.71M

Avg Vol (3M)

$522.53K

Beta

0.65

Div Yield

-

ANGO Company Profile


AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

748

IPO Date

Jun 01, 2004

Website

ANGO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceMay 24May 22May 21
Med Device$197.51M$237.50M-
Med Tech$106.40M$78.72M-
Endovascular Therapies--$135.08M
Oncology Surgery--$54.62M

Fiscal year ends in May 24 | Currency in USD

ANGO Financial Summary


May 24May 23May 22
Revenue$303.91M$338.75M$316.22M
Operating Income$-33.84M$-19.23M$-19.01M
Net Income$-184.35M$-52.44M$-26.55M
EBITDA$-6.13M$11.64M$10.34M
Basic EPS$-4.59$-1.33$-0.68
Diluted EPS$-4.59$-1.33$-0.68

Fiscal year ends in May 24 | Currency in USD

Latest Earnings Call Transcripts


Q4 24Jul 16, 24 | 10:35 AM
Q3 24Apr 04, 24 | 11:11 AM
Q2 24Jan 05, 24 | 10:26 AM

Peer Comparison


TickerCompany
MMSIMerit Medical Systems, Inc.
COOThe Cooper Companies, Inc.
ATRCAtriCure, Inc.
KRMDKORU Medical Systems, Inc.
AKYAAkoya Biosciences, Inc.
ATRIAtrion Corporation
NVSTEnvista Holdings Corporation
HAEHaemonetics Corporation
NSTGNanoString Technologies, Inc.
ICUIICU Medical, Inc.
ATRAptarGroup, Inc.